acute rejection

A-770041 is an orally active and selective Lck inhibitor that inhibits concanavalin A-stimulated IL-2 production in whole blood and prevents cardiac allograft rejection. A-770041 reduces pulmonary fibrosis by inhibiting TGF-β production in regulatory T cells.

Muromonab (OKT3) is a murine monoclonal antibody targeting CD3 receptors, blocking all cytotoxic T-cell functions. It reverses acute organ transplant rejection and is used in studies of acute graft rejection.

BTI-322 is a rat monoclonal IgG2b targeting the CD2 antigen on T cells and NK cells. It effectively blocks primary and memory alloantigen proliferative responses in vitro and identifies over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemia. BTI-322 has immunosuppressive activity and suppresses T-cell responses to allogeneic cells in vitro, serving as a T-cell depleting agent. It is used in research on kidney transplant rejection and steroid-resistant acute graft-versus-host disease.